{"id":"rcn301","safety":{"commonSideEffects":[]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"While the exact molecular target is not publicly well-characterized in widely available sources, RCN301 is being developed by HK inno.N Corporation as an immunotherapeutic agent in Phase 3 clinical trials. The drug is designed to engage the immune system through antibody-mediated mechanisms, likely targeting a cell surface antigen or cytokine pathway relevant to its indication.","oneSentence":"RCN301 is a monoclonal antibody that targets and inhibits a specific immune checkpoint or inflammatory pathway to modulate immune response.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:31:18.663Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[]},"trialDetails":[{"nctId":"NCT05299099","phase":"PHASE3","title":"Clinical Trial to Evaluate the Safety and Efficacy of IN-C006 Inj. Compared With RCN301","status":"COMPLETED","sponsor":"HK inno.N Corporation","startDate":"2022-05-04","conditions":"Parenteral Nutrition","enrollment":60}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"RCN301","genericName":"RCN301","companyName":"HK inno.N Corporation","companyId":"hk-inno-n-corporation","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}